A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).
Prostate Cancer
DRUG: Galeterone|DRUG: Enzalutamide
Radiographic Progression-free survival, ≥ 8 months
Overall Survival, ≥ 8 months|Time to Initiation of Cytotoxic Chemotherapy, ≥ 8 months
Skeletal-related Events, ≥ 8 months|Safety measured by clinical safety laboratories and adverse events, ≥ 8 months|Prostate Specific Antigen (PSA) Response ≥ 50%, ≥ 8 months|Time to PSA progression, ≥ 8 months|Time to ECOG deterioration, ≥ 8 months|Best Overall Response by RECIST 1.1, ≥ 8 months
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).